- Take this survey if you are living with hep C/if you have had hep C.
- Take this survey if you are a caregiver or loved one of someone who is living with hep C/had hep C.
- Sofosbuvir / Velpatasvir Information is Here.
The above survey links will only remain open until April 27th, 2016, so please complete a survey and share the survey links with others ASAP.
The Drug Approval Process is Seeking Patient and Caregiver Input
The Canadian Agency for Drugs and Technologies in Health (CADTH) wants to hear from you! They are currently reviewing the hep C treatment sofosbuvir / velpatasvir. As part of their review, they are seeking patient and caregiver input about hep C and hep C treatments from Canadian patient groups. Therefore, we, the Pacific Hep C Network (PHCN), are seeking your thoughts, opinions, and experiences for our patient group input report.
More information about CADTH and patient group reports is below.
PHCN’s Sofosbuvir / Velpatasvir Patient Input Surveys
There are two PHCN Input Surveys
The first survey was written for those with hep C or those who have had hep C. It includes 14 questions, some multiple choice, and is divided into 4 sections. The most important of these sections are ‘Section 2 of 4: Your Expectations of Sofosbuvir / Velpatasvir’ and 
‘Section 3 of 4: Your Experience with Sofosbuvir / Velpatasvir’, if you have been treated with sofosbuvir / velpatasvir. If you haven’t taken sofosbuvir / velpatasvir, the survey lets you skip this section.
The second survey was written for loved ones or caregivers of those living with hep C/have had hep C. It includes 7 questions divided into 2 sections.
If the surveys don’t focus on something you would like to add, please use a textbox and include it as one of your answers. Some of the questions require answers but others were written to, hopefully, help you share your experiences and voice your opinion.
Survey responses are anonymous (we don’t know your name or other information about you). The information gathered will be used as part of the sofosbuvir / velpatasvir patient group input report for CADTH.
By completing the survey you accept that PHCN can use the information gathered by it in our patient group input report for CADTH.
The survey links will only remain open until April 27th, so please complete a survey and share the survey links with others ASAP.
About Patient Group Input Reports Requested by CADTH
Within the Canadian drug approval process, Health Canada first evaluates a drug’s safety, clinical effectiveness, and its manufacturing process. The Common Drug Review (CDR) by CADTH then assesses the treatment’s clinical and cost-effectiveness as it compares to other treatments.
During Common Drug Reviews, CADTH requests patient input reports. These patient input reports help ensure that health outcomes and issues important to patients are incorporated into the Common Drug Review process in a formal and meaningful way.
They help ensure that patients and their loved ones are a part of the drug review process!
Email the Hepatitis C Treatment Information Project for more information about the surveys or for more information about sofosbuvir / velpatasvir.
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.